Company profile
Genetic Testing UK | Myogenes
Genetic testing thats proven to provide invaluable insights into your own unique and individual genetic makeup. Call us today 020 8387 1266
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
AA01 | Transaction MzUxMjgwMTMxOWFkaXF6a2N4
Published 26 Mar 2026 16:02
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0NTExNTM3MWFkaXF6a2N4
Published 27 Nov 2024 11:23
CS01 | Transaction MzQ0MzA0MTY0NGFkaXF6a2N4
Published 13 Nov 2024 10:53
SH01 | Transaction MzQ0MjgzMDk4MWFkaXF6a2N4
Published 12 Nov 2024 03:50
SH01 | Transaction MzQ0MTA5MjI5N2FkaXF6a2N4
Published 28 Oct 2024 10:30
RESOLUTIONS | Transaction QUREWE0zMVNhZGlxemtjeA | Paper/PDF filed
Published 28 Oct 2024 06:43
RESOLUTIONS | Transaction QUREWE0zMjBhZGlxemtjeA | Paper/PDF filed
Published 28 Oct 2024 06:42
CH01 | Transaction MzQzNzAyNzA2OGFkaXF6a2N4
Published 27 Sep 2024 02:47
CH01 | Transaction MzQzNjY5ODI0OWFkaXF6a2N4
Published 20 Sep 2024 01:41
TM01 | Transaction MzQzMjEzNjE2NmFkaXF6a2N4
Published 14 Aug 2024 10:43
Company registered at Companies House
1 Dec 2024 to 30 Nov 2025
The Myogenes Clozapine Test is a groundbreaking innovation aimed at revolutionising the management of treatment-resistant schizophrenia (TRS), which affects approximately 30% of schizophrenia cases globally. This comprehensive genetic analysis tool addresses the ineffective trial-and-error approach currently used in TRS treatment. Key innovations include:...
